FindTrial
Sign In

Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5 -

Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5 -

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221438
Enrollment
Unknown
Registered
2011-04-21
Start date
2011-04-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for colonoscopy

Interventions

investigational material(s) Generic name etc : AJG522 INN of investigational material : Therapeutic category code : 799 Agents for not mainly purpose of therapeutic, n.e.c. Dosage and Administration

Sponsors

Ajinomoto Pharmaceuticals Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients scheduled for colonoscopy.

Exclusion criteria

Exclusion criteria: - Presence or suspicion of gastrointesinal ileus, intestinal perforation or toxic megacolon. - Renal impairment.

Design outcomes

Primary

MeasureTime frame
Colon cleansing effect. Colon cleansing effect will be assessed by the colonoscopy.—

Secondary

MeasureTime frame
Dosage of investigational product administration Cleansing time—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026